Author response for "Comparing a Daily vs. Weekly Titration Algorithm in People with Type 2 Diabetes Switching from Basal Insulin to iGlarLixi in the LixiLan ONE CAN Randomized Trial"
crossref(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
crossref(2022)